Vir Biotechnology Inc

-1.09 (-2.71%)
Products, Regulatory

Vir Biotechnology Announces Start of ACTIV-3 Trial Evaluating VIR-7831 For Early Treatment Of COVID-19

Published: 12/17/2020 21:35 GMT
Vir Biotechnology Inc (VIR) - Vir Biotechnology - Vir-7831 is Being Evaluated in Global Phase 2/3 Comet-ice Trial for Early Treatment of Covid-19 in Adults at High Risk of Hospitalization.
Vir Biotechnology Inc - First Patient Has Been Dosed in a New Sub-trial of Nih Activ Program Phase 3 Clinical Trial.
Vir Biotechnology Inc - Comet Clinical Development Program for Vir-7831 Also Includes a Planned Phase 3 Trial for Prevention of Symptomatic Infection.